Last week, shares of Affymax got hammered when the company pulled back units of its sole commercial drug. Plus, find out what sent the biggest gainers skyward. More
Last week, Vivus slipped on a rejection from European regulators. Plus, find out why Chelsea Therapeutics and Infinity Pharmaceuticals soared. More
Last week, big names from Ziopharm Oncology to StemCells posted stellar gains, while Amicus Therapeutics shaked the positive trend with a hearty tumble. More
A good week for little guys Opexa Therapeutics and Hyperion Therapeutics and giant Biogen. But Hemispherx BioPharma and BioCryst Pharmaceuticals had downers. More
Among last week's highlights, Keryx jumps on a solid Phase III trial, Sarepta gets pounded from a fake tweet and Halozyme suffers from analyst downgrades. More
An analyst upgrade on DNDN lifted the shares 21% last Friday, but mid-stage trial failure of a colorectal drug sank ARQL 11% the same day. More
They were among the sector's big newsmakers last week, with Acadia, Oncolytics and Acura Pharmaceuticals. More
Amarin Corp. slides on dashed buyout hopes, while Sarepta, Galena and others also faced serious setbacks. More
Acadia Pharmaceuticals leads the way with a week of eye-popping gains. Plus: Why Exelixis and Supernus took tough tumbles. More
While Regeneron soared on behind its macular degeneration treatment, Dynavax, Navidea and AspenBio suffered serious setbacks. More
Advertise With Us
Terms and Conditions
Disclosures and Disclaimers
More On InvestorPlace:
Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Copyright ©2014 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.